₹2,408.9
■ -3.35
As of 16 Jul 2026 · delayed
NSE Listed · Pharmaceuticals
J B Chemicals and Pharma (JBCHEPHARM)
Volume: 47,79,224Avg Vol 1W: 11,15,679Avg Vol 1M: 4,53,29652W Range:₹1,638.5₹2,525.5
Key Ratios
Checked 11h agoMarket Cap₹38,677 Cr
Current Price₹2,408.9
Previous Close₹2,412.25
High / Low (52w)₹2,525.5 / ₹1,638.5
Volume47,79,224
Avg Vol (1W)11,15,679
Avg Vol (1M)4,53,296
Stock P/E379.35
Book Value₹259.05
Dividend Yield91%
ROE17.06%
ROA14.28%
Revenue (TTM)—
Revenue Growth5.87%
Profit Margin17.1%
Total Debt₹0 Cr
Shares Outstanding16 Cr
Face Value₹1
EPS (TTM)₹44.75
P/B9.3
Debt / Equity0
50 DMA₹2,319.83
200 DMA₹2,143.26
Day change—
Price Chart
₹2,408.9▲ 37.47% · 1Y
2025-11-242026-07-16
20-day avg volume: 4.9L shares
Pros
- Healthy return on equity of 17.1%.
- Pays a dividend yield of 91.0%.
- Company is almost debt-free.
Cons
- Stock trades at a high P/E of 379.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,004 Cr | ₹1,001 Cr | ₹963 Cr | ₹949 Cr | ₹1,094 Cr | ₹1,085 Cr | ₹1,065 Cr | ₹904 Cr |
| EBITDA | ₹245 Cr | ₹239 Cr | ₹221 Cr | ₹194 Cr | ₹273 Cr | ₹281 Cr | ₹269 Cr | ₹163 Cr |
| Net Profit | ₹177 Cr | ₹175 Cr | ₹162 Cr | ₹146 Cr | ₹202 Cr | ₹208 Cr | ₹198 Cr | ₹101 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,685 Cr | ₹1,825 Cr | ₹2,155 Cr | ₹2,463 Cr | ₹3,159 Cr | ₹3,521 Cr | ₹3,956 Cr | ₹4,208 Cr |
| EBITDA | ₹292 Cr | ₹362 Cr | ₹604 Cr | ₹510 Cr | ₹591 Cr | ₹796 Cr | ₹899 Cr | ₹985 Cr |
| Net Profit | ₹193 Cr | ₹272 Cr | ₹448 Cr | ₹385 Cr | ₹410 Cr | ₹553 Cr | ₹660 Cr | ₹709 Cr |
| EPS | 23.54 | 34.2 | 57.96 | 49.82 | 52.34 | 34.85 | 41.56 | 44.45 |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹1,792 Cr | ₹1,821 Cr | ₹2,238 Cr | ₹2,607 Cr | ₹3,554 Cr | ₹3,994 Cr | ₹4,274 Cr | ₹4,969 Cr |
| Total Liabilities | ₹309 Cr | ₹383 Cr | ₹425 Cr | ₹469 Cr | ₹1,074 Cr | ₹1,071 Cr | ₹840 Cr | ₹809 Cr |
| Equity | ₹1,483 Cr | ₹1,438 Cr | ₹1,813 Cr | ₹2,139 Cr | ₹2,480 Cr | ₹2,923 Cr | ₹3,433 Cr | ₹4,159 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹259 Cr | ₹367 Cr | ₹457 Cr | ₹305 Cr | ₹721 Cr | ₹933 Cr | ₹1,103 Cr | ₹960 Cr |
| Investing | ₹-28 Cr | ₹24 Cr | ₹-231 Cr | ₹2 Cr | ₹-962 Cr | ₹-404 Cr | ₹-296 Cr | ₹-586 Cr |
| Financing | ₹-156 Cr | ₹-306 Cr | ₹-87 Cr | ₹-138 Cr | ₹357 Cr | ₹-385 Cr | ₹-580 Cr | ₹-123 Cr |
| Free Cash Flow | ₹259 Cr | ₹367 Cr | ₹457 Cr | ₹305 Cr | ₹721 Cr | ₹933 Cr | ₹1,103 Cr | ₹960 Cr |
Shareholding
Promoter 48.8% Institutions 37.72% Public 13.48%
Efficiency & Working Capital
ROCE23%
Interest Coverage172
Dividend Payout—
Debtor Days69 d
Inventory Days60 d
Payable Days34 d
Cash Conversion Cycle94 d
Working Capital Days129 d
Shareholding Details
As of 2026-03-31
Promoter48.8%
FII16.3%
DII21.4%
Institutions37.7%
Public13.5%
Promoter Pledge0%
No. of Shareholders74,043
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Jan 2026 | Jan 2026 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 53.8% | 53.8% | 53.8% | 53.7% | 53.7% | 47.8% | 47.7% | 47.6% | 47.5% | 48.8% | 48.8% | 48.8% |
| FIIs | 10.3% | 11.1% | 12.2% | 13.6% | 14.6% | 18.3% | 17.8% | 15.3% | 14.9% | 14.6% | 14.6% | 16.3% |
| DIIs | 18% | 18.4% | 17.6% | 16.8% | 16.4% | 18.7% | 19.6% | 22.8% | 23.4% | 22.7% | 22.7% | 21.4% |
| Public | 17.8% | 16.8% | 16.4% | 15.8% | 15.3% | 15.1% | 14.9% | 14.3% | 14.2% | 13.9% | 13.9% | 13.5% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 63,230 | 63,892 | 66,953 | 62,743 | 62,081 | 63,948 | 70,064 | 71,957 | 69,338 | 68,966 | 68,966 | 74,043 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Torrent Pharmaceuticals Limited | Shareholding of Promoter and Promoter Group | 48.8% | 7.84 Cr |
| Kotak Midcap Fund | Public Shareholding | 4.4% | 70,60,045 |
| Axis Mutual Fund Trustee Limited A/c Axis Mutual Fund A/c Axis Small Cap Fund | Public Shareholding | 3.8% | 61,11,421 |
| Canara Robeco Mutual Fund A/c Canara Robeco Small Cap Fund | Public Shareholding | 2.2% | 34,89,226 |
| Government Pension Fund Global | Public Shareholding | 1.8% | 29,54,982 |
| Nippon Life India Trustee Ltd-a/c Nippon India Pharma Fund | Public Shareholding | 1.6% | 25,70,277 |
| Smallcap World Fund, Inc | Public Shareholding | 1.3% | 20,86,917 |
| Franklin India Small Cap Fund | Public Shareholding | 1.3% | 20,30,774 |
| Torrent Investments Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Urja 27 Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Australasia Pty Ltd | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Pharma Philippines Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Laboratories Torrent (malaysia) Sdn. Bhd., | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Pharma (thailand) Co. Ltd | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Do Brazil Ltda. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Pharma (uk) Ltd | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Laboratorios Torrent S.a. De C.v. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Tpl (malta) Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Pharma (malta) Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Curatio Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Farmacp¬utica Torrent Colombia Sas, Colombia | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Pharma Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Pharmaceuticals Chile Spa | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent International Lanka (pvt) Ltd | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Torrent Pharma Gmbh | Shareholding of Promoter and Promoter Group | 0% | 0 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Torrent Pharmaceuticals Limited | 0 | 0% | 2026-03-31 |
| Torrent Investments Limited | 0 | 0% | 2026-03-31 |
| Torrent Urja 27 Private Limited | 0 | 0% | 2026-03-31 |
| Torrent Australasia Pty Ltd | 0 | 0% | 2026-03-31 |
| Torrent Pharma Philippines Inc. | 0 | 0% | 2026-03-31 |
| Laboratories Torrent (malaysia) Sdn. Bhd., | 0 | 0% | 2026-03-31 |
| Torrent Pharma (thailand) Co. Ltd | 0 | 0% | 2026-03-31 |
| Torrent Do Brazil Ltda. | 0 | 0% | 2026-03-31 |
| Torrent Pharma (uk) Ltd | 0 | 0% | 2026-03-31 |
| Laboratorios Torrent S.a. De C.v. | 0 | 0% | 2026-03-31 |
| Tpl (malta) Limited | 0 | 0% | 2026-03-31 |
| Torrent Pharma (malta) Limited | 0 | 0% | 2026-03-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Sumit Bose | Non Executive & Independent Director | 2025 |
| Prashant Kumar. | Non-Executive & Non-Independent Director | 2025 |
| Nikhil Chopra | Whole Time Director & Chief Executive Officer | 2025 |
| SANDEEP PHADNIS | Vice President & Company Secretary | 2025 |
| Arun Duggal | Chairman & Independent Director | 2025 |
| GAURAV TREHAN | Non-Executive & Non-Independent Director | 2025 |
| Akshay Tanna | Non-Executive & Non-Independent Director | 2025 |
| Ashwani Puri | Non Executive & Independent Director | 2025 |
| Richa Arora | Independent Director | 2025 |
| Aman Mehta | Managing Director & Additional Director | 2025 |
| Amal Satyawan Kelshikar | Additional Director | 2025 |
| Hasmukh Patel | Additional Director | 2025 |
| Sudhir Menon | Additional Director | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals | ₹0 Cr | — |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹1 | 20 | 16 | 16 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-17 | Merger to Scrip Torrent Pharmaceuticals Ltd With Ratio of 51:100 | — |
| forthcoming | 2026-07-17 | Merger to Scrip Torrent Pharmaceuticals Ltd With Ratio of 51:100 | — |
| dividend | 2026-05-29 | ₹9.3 (930.0%) | Final |
| dividend | 2026-05-29 | ₹9.3 (930%) | Final |
| dividend | 2026-02-11 | ₹12.7 (1270%) | Interim |
| dividend | 2025-07-30 | ₹7 (700%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 216 | 0 | 0 | 528 | 6 | 907 |
| 2026 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 3 | 0 | 0 | 0 | 0 | 3 |
Insider / Designated-Person Trades
30 recent disclosure(s)
Parmeshwar Bhawarlalji BangDisposal · 1,300
Parmeshwar Bhawarlalji BangDisposal · 1,300
Sujay Kamlakar RajhansDisposal · 11,811
Stewart Graham BarkerAcquisition · 31,160
Torrent Pharmaceuticals LimitedAcquisition · 92,490
Stewart Graham BarkerDisposal · 92,490
Substantial Acquisitions (SAST)
4 disclosure(s)
Off Market23/01/2026 · 37,82,566
Off Market21/01/2026 · 7,44,81,519
Off Market21/01/2026 · 7,44,81,519
Market27/03/2025 · 89,83,145
Company Information
Incorporated1976
ChairmanArun Duggal
AuditorDeloitte Haskins & Sells LLP
Investor Email[email protected]; secretarial@jbpharm
📍 Neelam Centre 4th Floor, B-Wing Hind Cycle Road Worli, Mumbai, Maharashtra, 400030
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search